Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters

Roivant has done it again. The company is selling one of its subsidiaries, Dermavant, to Organon with more than $1 billion in potential milestone payments on the line. Around this time last year, Roivant sold another of its companies — called “Vants” — to Roche for $7 billion.